您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Ranolazine(CVT303,RS43285-003 Ranexa)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ranolazine(CVT303,RS43285-003 Ranexa)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Ranolazine(CVT303,RS43285-003 Ranexa)图片
CAS NO:95635-55-5
规格:≥98%
包装与价格:
包装价格(元)
500mg电议
1g电议
2g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)427.54
FormulaC24H33N3O4
CAS No.95635-55-5
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 86 mg/mL (201.2 mM)
Water: <1 mg/mL
Ethanol: 20 mg/mL (46.8 mM)
SMILESO=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2
SynonymsRanolazine Dihydrochloride; CVT 303, RS 43285-003; Ranolazine; S 43285; RS-43285; RS43285; CVT-303; CVT303; Ranexa; Latixa; Ranolazine HCl; Ranolazine Hydrochloride.
实验参考方法
In Vitro

In vitro activity: Ranolazine selectively inhibits late I(Na), reduces [Na(+)](i)-dependent calcium overload and attenuates the abnormalities of ventricular repolarisation and contractility that are associated with ischaemia/reperfusion and heart failure in myocardial cells. Ranolazine significantly and reversibly shortens the action potential duration (APD) of myocytes stimulated at either 0.5 Hz or 0.25 Hz in a concentration-dependent manner in left ventricular myocytes of dogs. Ranolazine at 5 and 10 mM reversibly shortens the duration of twitch contractions (TC) and abolished the after contraction. Ranolazine is found to bind more tightly to the inactivated state than the resting state of the sodium channel underlying I(NaL).

In VivoRanolazine (10 mM) significantly increases glucose oxidation 1.5-fold to 3-fold under conditions in which the contribution of glucoseto overall ATP production is low (low Ca, high FA, with insulin), high (high Ca, low Fa, with pacing), or intermediate in working hearts. Ranolazine similarly increases glucose oxidation in normoxic Langendorff hearts (high Ca, low FA; 15 mL/min). Ranolazine also significantly increases it during flow reduction to 7 mL/min, 3 mL/min, and 0.5 mL/min. Ranolazine significantly improves functional outcome, which is associated with significant increases in glucoseoxidation, a reversal of the increased FA oxidation seen in control reperfusions (versus preischemic), and a smaller but significant increase in glycolysis in reperfuse dischemic working hearts.
Animal modelRats: Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion
Formulation & DosageBolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection
References

Heart. 2006 Jul;92 Suppl 4:iv6-iv14; Circulation. 1996 Jan 1;93(1):135-42.